Shots: The P-IIb Study 201 trial evaluates the efficacy of lecanemab vs PBO in 856 patients with MCI due to AD and mild AD The results showed robust clearance of […]readmore
Shots: The sNDA is based on P-III EMPEROR-Preserved trial evaluates the safety and efficacy of Jardiance (10mg, qd) vs PBO in 5,988 patients with chronic HFpEF with/out diabetes The results […]readmore
Shots: The company has enrolled the 1st patient in a P-IIb trial to evaluate HZN-825 (300mg, qd/bid) in a ratio (1:1:1) in 300 patients with dcSSc for 52wks. The study […]readmore
Shots: The P-II PRISM-EXT, OLE of the PRISM3 trial evaluates CP101 vs PBO in 132 patients with recurrent CDI. Patients were enrolled in PRISM3 or directly enrolled after experiencing a […]readmore
Shots: The company has completed the enrolment in the P-III CONTACT-01 trial evaluating cabozantinib + atezolizumab in a ratio (1:1) in 366 patients with metastatic NSCLC prior treated with an […]readmore
Shots: The P-III SELECT-PsA 1 & 2 trials evaluate Rinvoq (15/30mg) vs PBO in patients with active PsA & axial involvement who have a history of intolerance or inadequate response […]readmore
Shots: The P-IV HER-MES study evaluates the tolerability & efficacy of Aimovig (70/140mg) vs topiramate in 777 patients with episodic or chronic migraine (≥4 migraine days/month) prior to not being […]readmore
Shots: The P-III JUNIPERA study evaluates secukinumab (75/150 mg) vs PBO in 86 children & adolescents aged 2-17yrs. with a confirmed diagnosis of JPsA or ERA The results showed a […]readmore
Shots: The P-III trial evaluates REGEN-COV (1200mg, SC) vs PBO in a ratio (1:1) in patients who lived in the same household with COVID-19 patients diagnosed within the prior 4 […]readmore
Shots: The P-III EMPEROR-Preserved trial evaluates the safety & efficacy of Jardiance (10mg, qd) vs PBO in 5,988 patients with chronic HFpEF with/out diabetes The results showed a reduction in […]readmore